FDA Oncology@FDAOncologyDr. Paul Kluetz @pkluetz of #FDAOncology discusses the issues surrounding the use of patient-reported outcomes in regulatory decision making #PRO #OCEPFDD http://j.mp/2KepmGK2:56 PM · Apr 26, 20182 Retweets1 Like